vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
FrontView REIT, Inc. is the larger business by last-quarter revenue ($16.5M vs $13.7M, roughly 1.2× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -24.9%, a 100.6% gap on every dollar of revenue.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
FVR vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $13.7M |
| Net Profit | $-4.1M | $10.4M |
| Gross Margin | — | — |
| Operating Margin | — | -86.5% |
| Net Margin | -24.9% | 75.7% |
| Revenue YoY | — | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $-0.19 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $13.7M | ||
| Q3 25 | $16.8M | $19.1M | ||
| Q2 25 | $17.6M | $8.1M | ||
| Q1 25 | $16.2M | $2.9M | ||
| Q3 24 | $14.5M | — |
| Q4 25 | $-4.1M | $10.4M | ||
| Q3 25 | $4.0M | $-16.3M | ||
| Q2 25 | $-2.9M | $-15.8M | ||
| Q1 25 | $-833.0K | $-13.3M | ||
| Q3 24 | $-2.4M | — |
| Q4 25 | — | -86.5% | ||
| Q3 25 | — | -10.1% | ||
| Q2 25 | — | -177.7% | ||
| Q1 25 | — | -472.7% | ||
| Q3 24 | — | — |
| Q4 25 | -24.9% | 75.7% | ||
| Q3 25 | 23.9% | -85.4% | ||
| Q2 25 | -16.5% | -196.0% | ||
| Q1 25 | -5.1% | -452.7% | ||
| Q3 24 | -16.7% | — |
| Q4 25 | $-0.19 | $-3.74 | ||
| Q3 25 | $0.19 | $-0.11 | ||
| Q2 25 | $-0.16 | $-0.16 | ||
| Q1 25 | $-0.06 | $-0.18 | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $137.5M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $35.3M |
| Total Assets | $854.4M | $154.7M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $137.5M | ||
| Q3 25 | $19.6M | $103.8M | ||
| Q2 25 | $8.4M | $121.6M | ||
| Q1 25 | $3.3M | $89.1M | ||
| Q3 24 | — | — |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q3 24 | — | — |
| Q4 25 | $391.2M | $35.3M | ||
| Q3 25 | $385.2M | $-8.1M | ||
| Q2 25 | $369.9M | $7.1M | ||
| Q1 25 | $324.7M | $10.7M | ||
| Q3 24 | $1.0K | — |
| Q4 25 | $854.4M | $154.7M | ||
| Q3 25 | $846.8M | $133.7M | ||
| Q2 25 | $856.5M | $133.8M | ||
| Q1 25 | $860.8M | $103.7M | ||
| Q3 24 | $1.0K | — |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $-2.0M |
| Free Cash FlowOCF − Capex | — | $-2.1M |
| FCF MarginFCF / Revenue | — | -15.3% |
| Capex IntensityCapex / Revenue | — | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $-2.0M | ||
| Q3 25 | $8.3M | $-17.5M | ||
| Q2 25 | $9.3M | $-14.5M | ||
| Q1 25 | $8.1M | $29.0M | ||
| Q3 24 | — | — |
| Q4 25 | — | $-2.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-14.9M | ||
| Q1 25 | — | $29.0M | ||
| Q3 24 | — | — |
| Q4 25 | — | -15.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -184.0% | ||
| Q1 25 | — | 988.3% | ||
| Q3 24 | — | — |
| Q4 25 | — | 0.7% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 5.0% | ||
| Q1 25 | — | 0.8% | ||
| Q3 24 | — | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
